Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1983 Jun;10(2):177–181.

Hypertrophic Obstructive Cardiomyopathy: Hemodynamic Improvement with Intravenous Verapamil

Stephen Jay Roth 1, Co-Burn J Porter 1, Larry A Latson 1
PMCID: PMC341633  PMID: 15227134

Abstract

We report the reduction in left ventricular outflow tract gradient following the intravenous administration of verapamil to two pediatric patients with hypertrophic obstructive cardiomyopathy. Traditional therapy with beta adrenergic antagonists was relatively contraindicated in both patients. In a 15-year-old patient, the left ventricular outflow tract gradient decreased from 160 torr, at rest, to 45 torr during the verapamil infusion. In a 3-year-old boy, there was a reduction in the left ventricular outflow tract gradient from 60 torr, under basal conditions, to 10 torr during the intravenous verapamil infusion. We believe that verapamil may be effective in reducing the left ventricular outflow tract gradient in some pediatric patients with hypertrophic obstructive cardiomyopathy and may be useful in treating selected patients with this disorder.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonow R. O., Rosing D. R., Bacharach S. L., Green M. V., Kent K. M., Lipson L. C., Maron B. J., Leon M. B., Epstein S. E. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981 Oct;64(4):787–796. doi: 10.1161/01.cir.64.4.787. [DOI] [PubMed] [Google Scholar]
  2. Epstein S. E., Rosing D. R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981 Sep;64(3):437–441. doi: 10.1161/01.cir.64.3.437. [DOI] [PubMed] [Google Scholar]
  3. Fiddler G. I., Tajik A. J., Weidman W., McGoon D. C., Ritter D. G., Giuliani E. R. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol. 1978 Nov;42(5):793–799. doi: 10.1016/0002-9149(78)90099-1. [DOI] [PubMed] [Google Scholar]
  4. Goodwin J. F. An appreciation of hypertrophic cardiomyopathy. Am J Med. 1980 Jun;68(6):796–800. doi: 10.1016/0002-9343(80)90189-8. [DOI] [PubMed] [Google Scholar]
  5. Hanrath P., Mathey D. G., Kremer P., Sonntag F., Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol. 1980 Jun;45(6):1258–1264. doi: 10.1016/0002-9149(80)90487-7. [DOI] [PubMed] [Google Scholar]
  6. Maron B. J., Edwards J. E., Henry W. L., Clark C. E., Bingle G. J., Epstein S. E. Asymmetric septal hypertrophy (ASH) in infancy. Circulation. 1974 Oct;50(4):809–820. doi: 10.1161/01.cir.50.4.809. [DOI] [PubMed] [Google Scholar]
  7. Maron B. J., Henry W. L., Clark C. E., Redwood D. R., Roberts W. C., Epstein S. E. Asymetric septal hypertrophy in childhood. Circulation. 1976 Jan;53(1):9–19. doi: 10.1161/01.cir.53.1.9. [DOI] [PubMed] [Google Scholar]
  8. Maron B. J., Roberts W. C., Epstein S. E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982 Jun;65(7):1388–1394. doi: 10.1161/01.cir.65.7.1388. [DOI] [PubMed] [Google Scholar]
  9. Maron B. J., Tajik A. J., Ruttenberg H. D., Graham T. P., Atwood G. F., Victorica B. E., Lie J. T., Roberts W. C. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation. 1982 Jan;65(1):7–17. doi: 10.1161/01.cir.65.1.7. [DOI] [PubMed] [Google Scholar]
  10. Rosing D. R., Condit J. R., Maron B. J., Kent K. M., Leon M. B., Bonow R. O., Lipson L. C., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981 Sep;48(3):545–553. doi: 10.1016/0002-9149(81)90086-2. [DOI] [PubMed] [Google Scholar]
  11. Rosing D. R., Kent K. M., Borer J. S., Seides S. F., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979 Dec;60(6):1201–1207. doi: 10.1161/01.cir.60.6.1201. [DOI] [PubMed] [Google Scholar]
  12. Rosing D. R., Kent K. M., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979 Dec;60(6):1208–1213. doi: 10.1161/01.cir.60.6.1208. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES